NCT01336634 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 84
- group Id
- BG001
- value
- 57
- group Id
- BG002
- value
- 36
- group Id
- BG003
- value
- 177
- units
- Participants
- groups
- description
- Participants with or without prior systemic anti-cancer therapy received Dabrafenib 150 mg BID until disease progression, death, or unacceptable adverse event(s) (AEs) or investigator discretion to discontinue or decision to crossover from monotherapy to combination therapy.
- id
- BG000
- title
- Cohort A (Dabrafenib Monotherapy): Dabrafenib Monotherapy 150mg BID
- description
- Participants who had received 1-3 prior lines of systemic anti-cancer therapies for advanced stage/metastatic disease received Dabrafenib 150 mg BID and Trametinib 2 mg once daily (OD). Treatment continued until disease progression, death, or unacceptable AEs or investigator discretion to discontinue.
- id
- BG001
- title
- Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD
- description
- Participants who had not received any prior systemic anti-cancer for metastatic disease therapies were given Dabrafenib 150 mg BID and Trametinib 2 mg OD. Treatment continued until disease progression, death, or unacceptable AEs or at investigator discretion to discontinue.
- id
- BG002
- title
- Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 10.51
- value
- 64.8
- group Id
- BG001
- spread
- 10.14
- value
- 65.1
- group Id
- BG002
- spread
- 11.00
- value
- 67.8
- group Id
- BG003
- spread
- 10.50
- value
- 65.5
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 44
- group Id
- BG001
- value
- 28
- group Id
- BG002
- value
- 22
- group Id
- BG003
- value
- 94
- title
- Female
- measurements
- group Id
- BG000
- value
- 40
- group Id
- BG001
- value
- 29
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 83
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 64
- group Id
- BG001
- value
- 49
- group Id
- BG002
- value
- 30
- group Id
- BG003
- value
- 143
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 18
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 25
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- title
- African American Heritage
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- Native Hawaiian or other Pacific islander
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- title
- Black or African American
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- title
- Other
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 20
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 50
- title
- Grade 0
- measurements
- group Id
- BG000
- value
- 52
- group Id
- BG001
- value
- 35
- group Id
- BG002
- value
- 22
- group Id
- BG003
- value
- 109
- title
- Grade 1
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 18
- title
- Grade 2
- description
- The Eastern Cooperative Oncology Group Performance Status (ECOG PS) score classifies participants according to their functional impairment, with scores ranging from 0 (fully active) to 5 (dead). ECOG PS: 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50% of waking hours
- param Type
- COUNT_OF_PARTICIPANTS
- title
- ECOG Performance Status
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 84
- group Id
- BG001
- value
- 57
- group Id
- BG002
- value
- 36
- group Id
- BG003
- value
- 177
- units
- Participants
- groups
- description
- Participants with or without prior systemic anti-cancer therapy received Dabrafenib 150 mg BID until disease progression, death, or unacceptable adverse event(s) (AEs) or investigator discretion to discontinue or decision to crossover from monotherapy to combination therapy.
- id
- BG000
- title
- Cohort A (Dabrafenib Monotherapy): Dabrafenib Monotherapy 150mg BID
- description
- Participants who had received 1-3 prior lines of systemic anti-cancer therapies for advanced stage/metastatic disease received Dabrafenib 150 mg BID and Trametinib 2 mg once daily (OD). Treatment continued until disease progression, death, or unacceptable AEs or investigator discretion to discontinue.
- id
- BG001
- title
- Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD
- description
- Participants who had not received any prior systemic anti-cancer for metastatic disease therapies were given Dabrafenib 150 mg BID and Trametinib 2 mg OD. Treatment continued until disease progression, death, or unacceptable AEs or at investigator discretion to discontinue.
- id
- BG002
- title
- Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 10.51
- value
- 64.8
- group Id
- BG001
- spread
- 10.14
- value
- 65.1
- group Id
- BG002
- spread
- 11.00
- value
- 67.8
- group Id
- BG003
- spread
- 10.50
- value
- 65.5
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 44
- group Id
- BG001
- value
- 28
- group Id
- BG002
- value
- 22
- group Id
- BG003
- value
- 94
- title
- Female
- measurements
- group Id
- BG000
- value
- 40
- group Id
- BG001
- value
- 29
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 83
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 64
- group Id
- BG001
- value
- 49
- group Id
- BG002
- value
- 30
- group Id
- BG003
- value
- 143
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 18
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 25
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- title
- African American Heritage
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- Native Hawaiian or other Pacific islander
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- title
- Black or African American
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- title
- Other
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 20
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 50
- title
- Grade 0
- measurements
- group Id
- BG000
- value
- 52
- group Id
- BG001
- value
- 35
- group Id
- BG002
- value
- 22
- group Id
- BG003
- value
- 109
- title
- Grade 1
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 18
- title
- Grade 2
- description
- The Eastern Cooperative Oncology Group Performance Status (ECOG PS) score classifies participants according to their functional impairment, with scores ranging from 0 (fully active) to 5 (dead). ECOG PS: 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50% of waking hours
- param Type
- COUNT_OF_PARTICIPANTS
- title
- ECOG Performance Status
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Independent clinical review pending · Not medical advice
Triangle